Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab...
Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
About this item
Full title
Author / Creator
Publisher
Los Angeles, CA: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
Los Angeles, CA: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Background:
Kidney transplant recipients are given induction therapy to rapidly reduce the immune response and prevent rejection. Guidelines recommend that an interleukin-2 receptor antibody (basiliximab) be the first-line agent and that a lymphocyte-depleting agent (antithymocyte globulin [ATG]) be reserved for those at high immunologic risk.
Alternative Titles
Full title
Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_65b0842772c64e01bcf432589a6418d2
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_65b0842772c64e01bcf432589a6418d2
Other Identifiers
ISSN
2054-3581
E-ISSN
2054-3581
DOI
10.1177/2054358120964061
